BMC Infectious Diseases
Volume 18, Issue 1, 2018
Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: A focus on migrants from anti-HCV endemic countries (Article) (Open Access)
Falla A.M.* ,
Ahmad A.A. ,
Duffell E. ,
Noori T. ,
Veldhuijzen I.K.
-
a
University Medical Center Rotterdam, Department of Public Health, Erasmus MC, Rotterdam, Netherlands, Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, Rotterdam, LP, 3000, Netherlands
-
b
Hamburg University of Applied Sciences, Faculty Life Sciences / Public Health Research, Department of Health Sciences, Ulmenliet 20, Hamburg, 21033, Germany, University Medical Center Hamburg-Eppendorf, Department of Internal Medicine, Martinistr 52, Hamburg, 20246, Germany
-
c
European Centre for Disease Prevention and Control, Granits väg 8, Solna, 171 65, Sweden
-
d
European Centre for Disease Prevention and Control, Granits väg 8, Solna, 171 65, Sweden
-
e
Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, Rotterdam, LP, 3000, Netherlands, Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Sweden
Abstract
Background: Increasing the proportion diagnosed with and on treatment for chronic hepatitis C (CHC) is key to the elimination of hepatitis C in Europe. This study contributes to secondary prevention planning in the European Union/European Economic Area (EU/EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among migrants living in the EU/EEA and born in endemic countries, defining the most affected migrant populations, and assessing whether country of birth prevalence is a reliable proxy for migrant prevalence. Methods: Migrant country of birth and population size extracted from statistical databases and anti-HCV prevalence in countries of birth and in EU/EEA countries derived from a systematic literature search were used to estimate caseload among and most affected migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was assessed via a systematic literature search. Results: Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom were born in endemic (anti-HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence in migrants from endemic countries residing in the EU/EEA is estimated at 2.3%/1.6%, corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/EEA. The highest number of cases is found among migrants from Romania and Russia (50-60,000 cases each) and migrants from Italy, Morocco, Pakistan, Poland and Ukraine (25-35,000 cases each). Ten studies reporting prevalence in migrants in Europe were identified; in seven of these estimates, prevalence was comparable with the country of birth prevalence and in three estimates it was lower. Discussion: Migrants are disproportionately affected by CHC, account for a considerable number of CHC infections in EU/EEA countries, and are an important population for targeted case finding and treatment. Limited data suggest that country of birth prevalence can be used as a proxy for the prevalence in migrants. © 2018 The Author(s).
Author Keywords
Index Keywords
Link
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040348595&doi=10.1186%2fs12879-017-2908-5&partnerID=40&md5=6dad60fe7e066687817d955902f4385b
DOI: 10.1186/s12879-017-2908-5
ISSN: 14712334
Cited by: 7
Original Language: English